- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
C. Nucci et al. (Eds.)
Progress in Brain Research, Vol. 173
ISSN 0079-6123
Copyright r 2008 Elsevier B.V. All rights reserved
CHAPTER 1
Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
Claudio Cedrone , Raffaele Mancino, Angelica Cerulli, Massimo Cesareo and
Carlo Nucci
Physiopathological Optics, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Abstract: Certain general conclusions can be drawn from a series of 56 studies on glaucoma prevalence. Even in the most recently published studies the rate of undiagnosed glaucoma is particularly high. Another fairly constant finding is the discrepancy between the clinical and epidemiologic diagnoses of glaucoma. The prevalence of primary open-angle glaucoma (POAG) has been increasing, and this trend is undoubtedly due at least in part to advances in diagnostic technology. The decreasing prevalence of primary angle-closure glaucoma (PACG) is due to the adoption of more stringent criteria for the diagnosis of this form of glaucoma. Prevalence increases proportionately with age for each racial group. African or African origin populations had the highest POAG prevalence at all ages but the increase in prevalence of POAG is steeper for white populations. PACG is commonest in Asian ethnic groups, with the exception of the Japanese. Low-tension glaucoma (LTG) is quite common in the Japanese population. Over 80% of those with PACG live in Asia, while POAG disproportionately affects those of African derivation. Women are more affected by glaucoma. Very few incidence studies have been completed, because the cost of examining large samples is high. There are only two recent studies conducted on persons of African descent in Barbados (West Indies) and on white inhabitants of Rotterdam (Netherlands). Risk of incident glaucoma was highest among persons classified as having suspect POAG at baseline, followed by those with ocular hypertension. No difference in incidence of POAG between men and women was found. The more recent studies which included routine visual-field testing reveal rates of blinding glaucoma o10% in many countries, including those that are developing.
Keywords: glaucoma; prevalence; incidence; blindness
Introduction
The main objectives of an epidemiological study are to describe the frequency of a disease in a given population and to identify risk factors that may be associated with the disease. As with many other
Corresponding author. Tel.: +39 0672596144; Fax: +39 062026232; E-mail: cedrone@uniroma2.it
diseases, the biggest methodological problem encountered in studies that aim to investigate the prevalence and incidence of glaucoma is the definition of the disease.
Prevalence of glaucoma
Since the 1920s, numerous studies have been conducted to determine the prevalence of glaucoma. In
DOI: 10.1016/S0079-6123(08)01101-1 |
3 |
4
many cases, however, the participants were simply persons with high intraocular pressure (IOP) because in those days glaucoma was regarded as synonymous with ocular hypertension (HIOP). After the introduction of gonioscopy (Barkan, 1938), two types of glaucoma were distinguished: primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). Most of the prevalence studies cited above focused on POAG, which — according to the initial findings — affected 2% of individuals over 40 years of age. This figure reflected the number of subjects with HIOP (i.e., IOPW20 mmHg, a figure that represents the statistical mean of values observed in numerous population studies increased by a sum equal to twice the standard deviation of the mean), which is not always associated with optic neuropathy, a hallmark of glaucoma. It failed to include persons who did have glaucomatous changes in the optic disc and in the visual fields despite the fact that their IOP was statistically normal.
Since 1972, most of the figures cited above have been considered inaccurate representations of the prevalence of POAG because the studies that generated them failed to respect certain methodological requisites (Khan, 1972): (1) the study population must be well defined, and no subgroup should be systematically excluded from the investigation; (2) the criteria used to define persons affected by the disease must be clearly described;
(3)the number of subjects in the population who are eligible for enrollment must be specified; and
(4)the participation rate, i.e., the percentage of subjects actually examined must be reported (if possible, for each sex and age group).
The first study that was unanimously acknowledged to be well designed and appropriately conducted was the 1963 Ferndale Glaucoma Survey (Hollows and Graham, 1966), which examined 92% of the eligible population of a town in South Wales. POAG was diagnosed in subjects who presented an IOP of W 20 mmHg, cupping of the optic disc, and visual-field defects. This study introduced the concept of routine visual-field testing with the Friedman analyzer (even though this testing was done on only one out of three patients). This approach led to the identification of certain cases of low-tension
glaucoma (LTG), half of which were subsequently reclassified as POAG based on IOPs observed at later visits. In addition, the study revealed that the majority of cases of glaucoma are primary and of the open-angle type.
So far, 55 other population-based surveys have been conducted in the populations of an entire town, village, region, or nation or in those selected with a clearly defined random or clustered sampling procedure. The racial or ethnic groups examined in these studies can be broadly grouped into the following categories: Asian (Alsbirk, 1973; Arkell et al., 1987; Hu, 1989; Shiose et al., 1991; Rauf et al., 1994; Foster et al., 1996, 2000; Jacob et al., 1998; Dandona et al., 2000a, b; Metheetrairut et al., 2002; Bourne et al., 2003; Ramakrishnan et al., 2003; Iwase et al., 2004; Rahman et al., 2004; Yamamoto et al., 2005; Raychaudhuri et al., 2005; Vijaya et al., 2005, 2006, 2008a, b; He et al., 2006; Casson et al., 2007); Black (Wallace and Lovell, 1969; Mason et al., 1989; Tielsch et al., 1991; Wormald et al., 1994; Leske et al., 1994; Buhrmann et al., 2000; Rotchford and Johnson, 2002; Ekwerekwu and Umeh, 2002; Rotchford et al., 2003; Ntim-Amponsah et al., 2004; Friedman et al., 2006); Hispanic (Quigley et al., 2001; Anton et al., 2004; Varma et al., 2004); Mixed (Salmon et al., 1993; Sakata et al., 2007); White (Hollows and Graham, 1966; Bankes et al., 1968; Leibowitz et al., 1980; Bengtsson, 1981; Martinez et al., 1982; Gibson et al., 1985; Tielsch et al., 1991; Ringvold et al., 1991; Klein et al., 1992; Coffey et al., 1993; Dielemans et al., 1994; Leske et al., 1994; Hirvela et al., 1994; Giuffre´et al., 1995; Ekstrom, 1996; Mitchell et al., 1996; Cedrone et al., 1997; Bonomi et al., 1998; Reidy et al., 1998; Wensor et al., 1998; Kozobolis et al., 2000; Friedman et al., 2006; Sakata et al., 2007; Topouzis et al., 2007). Prevalence rates of POAG and PACG are reported in Tables 1–3.
These studies varied widely in terms of the eye examination methods and case definitions used, in particular the criteria adopted for defining glaucomatous nerve damage. With the advent of automated perimetry, the definitions of glaucoma used in epidemiologic studies improved. With manual kinetic field testing, the outcome of the examination and the reliability of findings were
|
|
|
|
|
5 |
Table 1. Glaucoma prevalence studies in Asian racial group |
|
|
|
|
|
|
|
|
|
|
|
Author |
Location |
Country |
Age |
% POAG |
% PACG |
|
|
|
|
|
|
Alsbirk (1973) |
Umanaq |
Greenland |
40+ |
0.3 |
4.8 |
Arkell et al. (1987) |
Alaska |
USA |
40+ |
0.2 |
2.7 |
Hu (1989) |
Shunyi, Beijing |
China |
40+ |
0.03 |
1.4 |
Shiose et al. (1991) |
Whole country |
Japan |
40+ |
2.6 |
0.3 |
Rauf et al. (1994) |
Southall, London |
UK |
30+ |
2.7 |
0.0 |
Foster et al. (1996) |
Hovsgol |
Mongolia |
40+ |
0.5 |
1.5 |
Jacob et al. (1998) |
Vellore, |
India |
30–60 |
0.4 |
4.3 |
Foster et al. (2000) |
Tanjong Pagar District |
Singapore |
40+ |
1.8 |
1.1 |
Dandona et al. (2000a, b) |
Andhra Pradesh |
India |
40+ |
2.6 |
1.1 |
Metheetrairut et al. (2002) |
Bangkok |
Thailand |
60+ |
3.5 |
2.5 |
Bourne et al. (2003) |
Rom Klao, Bangkok |
Thailand |
50–70 |
2.3 |
0.9 |
Ramakrishnan et al. (2003) |
Aravind, |
India |
40+ |
1.2 |
0.5 |
Iwase et al. (2004) |
Tajimi |
Japan |
40+ |
3.9 |
ns |
Rahman et al. (2004) |
Dhaka |
Bangladesh |
35+ |
1.9 |
0.3 |
Yamamoto et al. (2005) |
Tajimi |
Japan |
40+ |
ns |
0.6 |
Raychaudhuri et al. (2005) |
West Bengala |
India |
50+ |
3.0 |
0.2 |
Vijaya et al. (2005, 2006) |
Tamil Nadu region |
India |
40+ |
1.6 |
0.9 |
He et al. (2006) |
Guangzhou city |
China |
50+ |
2.1 |
1.5 |
Casson et al. (2007) |
Meiktila district |
Myanmar |
40+ |
2.0 |
2.5 |
Vijaya et al. (2008a, b) |
Chennai city |
India |
40+ |
3.5 |
0.9 |
|
|
|
|
|
|
Note: POAG, primary open angle glaucoma; PACG, primary angle closure glaucoma; ns, not stated.
Table 2. Glaucoma prevalence studies in Black, Hispanic, and Mixed racial group
Author |
Location |
Country |
Age |
% POAG |
% PACG |
|
|
|
|
|
|
Black: |
|
|
|
|
|
Wallace and Lovell (1969) |
Jamaica |
West Indies |
35+ |
1.4 |
0.35 |
Mason et al. (1989) |
St. Lucia |
West Indies |
30+ |
8.8 |
0.0 |
Tielsch et al. (1991) |
Baltimore |
USA |
40+ |
4.7 |
ns |
Wormald et al. (1994) |
London |
UK |
35+ |
3.7 |
ns |
Leske et al. (1994) |
Barbados |
West Indies |
40+ |
7.0 |
ns |
Buhrmann et al. (2000) |
Kongwa |
Tanzania |
40+ |
3.1 |
0.6 |
Rotchford and Johnson (2002) |
Kwazulu-Natal |
South Africa |
40+ |
2.7 |
0.1 |
Ekwerekwu and Umeh (2002) |
Alum-Inyi |
Nigeria |
30+ |
2.1 |
ns |
Rotchford et al. (2003) |
Temba |
South Africa |
40+ |
2.9 |
0.5 |
Ntim-Amponsah et al. (2004) |
Akwapim-South district |
Ghana |
30+ |
7.7 |
ns |
Friedman et al. (2006) |
Salisbury |
USA |
73+ |
20.0 |
ns |
Hispanic: |
|
|
|
|
|
Quigley et al. (2001) |
Nogales and Tucson |
USA |
40+ |
2.0 |
0.1 |
Anton et al. (2004) |
Segovia |
Spain |
40–79 |
2.1 |
ns |
Varma et al. (2004) |
Los Angeles |
USA |
40+ |
4.7 |
ns |
Mixed: |
|
|
|
|
|
Salmon et al. (1993) |
Mamre |
South Africa |
40+ |
1.5 |
2.3 |
Sakata et al. (2007) |
Piraquara City |
Brazil |
40+ |
3.8 |
0.8 |
|
|
|
|
|
|
Note: POAG, primary open angle glaucoma; PACG, primary angle closure glaucoma; ns, not stated.
6
Table 3. Glaucoma prevalence studies in White racial group
Author |
Location |
Country |
Age |
% POAG |
% PACG |
|
|
|
|
|
|
Hollows and Graham (1966) |
Ferndale |
Wales |
40+ |
0.4 |
0.1 |
Bankes et al. (1968) |
Bedford |
UK |
40+ |
0.8 |
0.2 |
Leibowitz et al. (1980) |
Framingham |
USA |
52+ |
1.6 |
ns |
Bengtsson (1981) |
Dalby |
Sweden |
55–69 |
0.9 |
0.0 |
Martinez et al. (1982) |
Gisborne |
New Zealand |
65–75 |
3.6 |
ns |
Gibson et al. (1985) |
Melton Mowbray |
UK |
76+ |
6.6 |
ns |
Tielsch et al. (1991) |
Baltimore |
USA |
40+ |
1.3 |
ns |
Ringvold et al. (1991) |
middle-Norway |
Norway |
65+ |
4.0 |
ns |
Klein et al. (1992) |
Beaver Dam |
USA |
43+ |
2.1 |
0.1 |
Coffey et al. (1993) |
Roscommon |
Ireland |
50+ |
1.9 |
0.1 |
Dielemans et al. (1994) |
Rotterdam |
The Netherlands |
55+ |
1.1 |
0.0 |
Leske et al. (1994) |
Barbados |
West Indies |
40+ |
0.8 |
ns |
Giuffre´et al. (1995) |
Casteldaccia |
Italy |
40+ |
1.2 |
ns |
Hirvela et al. (1994) |
Oulu |
Finland |
70+ |
3.0 |
ns |
Ekstrom (1996) |
Tierp |
Sweden |
65–74 |
3.8 |
ns |
Mitchell et al. (1996) |
Blue Mountains |
Australia |
50+ |
3.0 |
0.3 |
Cedrone et al. (1997) |
Ponza |
Italy |
40+ |
2.5 |
1.0 |
Bonomi et al. (1998) |
Egna-Neumarkt |
Italy |
40+ |
2.1 |
0.6 |
Reidy et al. (1998) |
North London |
UK |
65+ |
3.0 |
ns |
Wensor et al. (1998) |
Melbourne |
Australia |
40+ |
1.7 |
0.1 |
Kozobolis et al. (2000) |
Crete |
Greece |
40+ |
2.8 |
ns |
Friedman et al. (2006) |
Salisbury |
USA |
73+ |
8.5 |
ns |
Sakata et al. (2007) |
Piraquara City |
Brazil |
40+ |
2.1 |
0.8 |
Topouzis et al. (2007) |
Thessaloniki city |
Greece |
60+ |
3.8 |
ns |
|
|
|
|
|
|
Note: POAG, primary open angle glaucoma; PACG, primary angle closure glaucoma; ns, not stated.
dependent on the psychological/physical conditions of the patient and of the examiner. The automated examination allowed objective evaluation of the reliability of the findings, which are generally rated as good when false positive or false negative rates are r33% and loss of fixation rates are o20%. Furthermore, it was more sensitive and specific than manual perimetry and thus capable of detecting early visual-field changes that were missed with older methods.
The Dalby Study (1977–1978) deserves mention because it was the first study in which all participants underwent visual-field testing with the automated perimeter developed and validated by Heiji and Krakau, which is the prototype of the Humphrey perimeter (Bengtsson, 1981). As a result, all cases of LTG in the population examined in this study should have been diagnosed. Despite its improved reliability, visual-field testing with an automated perimeter had its drawbacks. For one thing, it prolonged the eye examination by approximately 30 min. Therefore,
in many of the less recent studies, visual fields were not tested in all participants because it represented a true ‘‘bottle-neck’’ in the examination scheme. With the recently introduced program based on the Swedish Interactive Threshold Algorithms (SITA), examination times are considerably shorter than those associated with the program based on the Full Threshold Algorithm. In the assessment of the central 301 of the visual field, the SITA Standard and SITA Fast programs reduce test times by 50% and 66%, respectively. More recently, the introduction of perimetry based on the frequency doubling technology (FDT) has allowed increasingly rapid detection of even earlier changes in the visual field (less than 2 min per eye).
These new methods for visual-field testing have drastically reduced the duration of eye examinations in prevalence studies. This factor is particularly important in research settings because the reliability of prevalence figures is inversely proportional to the time required for examination of the total sample. The prevalence of a disease is
calculated by dividing the number of cases ascertained at a given time by the number of subjects in the population at that time. If case ascertainment is significantly prolonged — e.g., 2 years — the onset of some of the cases identified near the end of the study may have occurred long after the beginning of the study. In theory, with respect to the initiation of the study, these would represent incident rather than prevalent cases. Furthermore, by the end of the 2-year ascertainment period, glaucoma might have developed in some subjects who were examined in the early phases of the study and found to be healthy.
Visual-field testing of only some of the participants in a study can obviously lead to underestimations of the prevalence of glaucoma (Mason et al., 1989). However, in a substantial number of subjects who do not have glaucoma, the results of field tests meet the criteria for abnormality. Therefore, use of these results without an examination of the optic disc can lead to overestimation of glaucoma prevalence. A thorough examination of the optic disc is a fundamental part of the threetiered system of evidence (Foster et al., 2002), which was recently used to categorize glaucoma in almost all recent population-based prevalence surveys (Bourne et al., 2003; Rotchford et al., 2003; Iwase et al., 2004; Rahman et al., 2004; Raychaudhuri et al., 2005; Yamamoto et al., 2005; Vijaya et al., 2005, 2006, 2008a, b; He et al., 2006; Casson et al., 2007; Topouzis et al., 2007; Sakata et al., 2007). The prototype system was discussed by the ISGEO Glaucoma classification working group at the congress of the International Society for Geographical and Epidemiological Ophthalmology held in Leeuwenhorst, the Netherlands, in June 1998.
The rationale underlying this new classification system is that, although the level of IOP is one of the most consistent risk factors for the presence of glaucoma, the concept that statistically raised IOP is a defining characteristic for glaucoma has been almost universally discarded. This is based on several population-based studies that document the typical disc and field damage of glaucoma in people with a statistically normal IOP and, conversely, people with statistically elevated IOP and no evidence of optic neuropathy (Foster et al., 2002). The authors proposed to follow this current
7
convention except for category 3 diagnosis, as detailed below. The diagnosis of glaucoma is made according to the following three categories:
Category 1 (structural and functional evidence): Eyes with a cup-to-disc ratio (CDR) or CDR asymmetry W97.5th percentile for the normal population, or a neuroretinal rim width reduced to o0.1 CDR (between 11 and 1 o’clock or 5 and 7 o’clock) that also showed a definite visual-field defect consistent with glaucoma.
Category 2 (advanced structural damage with unproved field loss): If the subject could not satisfactorily complete visual-field testing but had a CDR or CDR asymmetry W99.5th percentile for the normal population, glaucoma was diagnosed solely on the structural evidence. In diagnosing category 1 or 2 glaucoma, there should be no alternative explanation for CDR findings (dysplastic disc or marked anisometropia) or the visual-field defect (retinal vascular disease, macular degeneration, or cerebrovascular disease).
Category 3 (optic disc not seen. Field test impossible): If it is not possible to examine the optic disc, glaucoma is diagnosed if: (A) The visual acuity is o3/60 and the IOP W99.5th percentile, or (B) The visual acuity is o3/60 and the eye shows evidence of glaucoma filtering surgery, or medical records were available confirming glaucomatous visual morbidity.
POAG is therefore optic nerve damage meeting any of the three categories of evidence below, in an eye which does not have evidence of angle closure on gonioscopy, and where there is no identifiable secondary cause. PACG is optic nerve damage meeting any of the three categories of evidence above, in an eye which has evidence of angle closure on gonioscopy, according to the following
